AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.20 · Revenue $0.00 · 1 analysts
Est. EPS $-0.23 · Revenue $0.00 · 2 analysts
Est. EPS $-0.90 · Revenue $72.70M · 1 analysts
Est. EPS $-0.21 · Revenue $0.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-35.2M | +31.5% | +18.4% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-29.8M | +39.4% | +42.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.0% | — | — |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.87x | -18.4% | -8.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $62.0M | -32.7% | -6.6% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.16 vs -1.12 | -3.6% | -0.18 vs -0.24 | +25.0% |
| Revenue Surprise | $0 vs $33.2M | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | FitzPatrick Margaret M | director | Common Stock | A | 2,098 | $5.53 |
| Aug 24, 2026 | Trenor Cameron C. III | — | — | — | 0 | — |
| Aug 17, 2026 | Readnour Robin Shane | director | Common Stock | D | 18,706 | $6.01 |
| Aug 17, 2026 | Readnour Robin Shane | director | Common Stock | D | 16,696 | $6.01 |
| Aug 14, 2026 | Zakrzewski Joseph S | director | Common Stock | D | 405,880 | — |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Eric E. Easom | Co-Founder, Chief Executive Officer, President & Chairman of the Board | USD 943,313 | Male | 1968 | Active |
Lucy O. Day | CFO, & Principal Financial Officer | USD 633,580 | Female | 1960 | Active |
Josh Eizen | Chief Legal Officer, Chief Operating Officer & Corporate Secretary | USD 630,000 | Male | 1979 | Active |
Joseph S. Zakrzewski | Co-Founder & Independent Director | USD 51,500 | Male | 1962 | Active |
Sanjay Chanda | Chief Development Officer | — | — | 1966 | Active |
Sarah Williams | Vice President of Controller & Principal Accounting Officer | — | Female | 1988 | Active |
Michael R. K. Alley | Co-Founder, Senior Vice President of Research Fellow & Head of Biology | — | — | — | Active |
Vince Hernandez | Senior Vice President of Research & Head of Chemistry | — | Male | — | Active |
George Harrison Talbot FACP | Co-Founder & Senior Clinical Advisor | — | — | 1948 | Active |
NEW YORK, July 20, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders. The investigation seeks to determine whether AN2 Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company's oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) caused by infection with the parasite T. cruzi. Key findings from the two studies: In NHPs with naturally acquire.
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics we.
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2026. “This was an important quarter for AN2 as we announced an exciting new program in polycythemia vera that is planned to enter Phase 2 development in the third quarter of 2026. This pr.
